enforcement ·

TGA Targets Unlawful Import, Advertising of Rx Meds & SARMs

The TGA has issued over $126,000 in infringement notices for unlawful importation and advertising of prescription-only medicines, including penalties for SARMs advertising.

TGAenforcementimportationadvertisingprescription-medicinesSARMscompliance

The Australian Therapeutic Goods Administration (TGA) is stepping up its compliance activities, recently issuing 12 infringement notices totalling $126,720 to two companies and five individuals for alleged unlawful importation and advertising of prescription-only medicines. These actions, published in a TGA media release on 6 October 2026, underscore the regulator’s firm stance against non-compliant therapeutic goods activity.

The infringements covered a range of alleged contraventions of the Therapeutic Goods Act 1989. Notable examples included advertising of prescription medicines such as lovastatin, baricitinib, and ketamine by a Queensland-based entity, resulting in fines of $47,520. Further notices were issued for the unlawful importation of Mounjaro pens by a Victorian-based individual and prescription-only erectile dysfunction medicines by an individual in New South Wales.

Direct Action on SARMs Advertising

In a separate but highly relevant enforcement action, the TGA’s “Infringement notices” database confirms that Redback SARMs paid a fine for advertising prescription-only substances. This directly addresses the often-ambiguous space of Selective Androgen Receptor Modulators (SARMs) and signals the TGA’s willingness to pursue enforcement against entities promoting these compounds without regulatory approval. This action reinforces that, regardless of how they are marketed, SARMs are considered prescription-only substances in Australia, and their unlawful advertising carries penalties.

These recent actions are part of a broader push by the TGA to ensure the integrity of the supply chain for therapeutic goods and protect public health. The regulator consistently advises businesses and individuals to understand their legal obligations under the Act before importing, advertising, or supplying therapeutic goods.

Implications for Researchers and Importers

For Australian researchers, and those involved in the procurement of research compounds, these TGA actions serve as a critical reminder. The focus on “unlawful importation and advertising of prescription-only medicines” can directly encompass many peptide and SARM compounds that are not approved for supply in Australia. The explicit action against Redback SARMs highlights that the ‘research use only’ disclaimer often used by suppliers does not exempt them from TGA oversight, especially when advertising materials imply therapeutic benefits or encourage direct human use.

The regulatory environment is continuously tightening. Entities involved in the supply chain of these compounds must exercise extreme diligence to ensure compliance with Australian law, particularly regarding import restrictions and advertising prohibitions for unapproved or prescription-only therapeutic goods.

What to Watch

Expect continued vigilance from the TGA in this space. The regulator’s willingness to issue substantial fines and target specific categories like SARMs indicates a proactive enforcement strategy. Future actions are likely to focus on online advertising, social media promotion, and the importation pathways used for unapproved therapeutic goods. Monitoring official TGA media releases and their public infringement notices database will remain essential for staying abreast of developments.

Sources:

For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.